Researchers from the University of Toronto built model versions of both heart and liver tissues that function like real organs, using the new technology called AngioChip, a powerful platform for discovering and testing new drugs.
"Our liver actually produced urea and metabolised drugs," said Professor Milica Radisic.
Using the platform, they can connect the blood vessels of the two artificial organs, thereby modelling not just the organs themselves, but the interactions between them.
The researchers wanted to find ways to grow human tissues in the lab, under conditions that mimic a real person's body.
They developed unique methods for manufacturing small, intricate scaffolds for individual cells to grow on.
These artificial environments produce cells and tissues that resemble the real thing more closely than those grown lying flat in a petri dish.
"It's a fully three-dimensional structure complete with internal blood vessels. It behaves just like vasculature, and around it there is a lattice for other cells to attach and grow," said Radisic.
The layers, which resemble the computer microchips, are then stacked into a 3D structure of synthetic blood vessels. As each layer is added, ultra-violet (UV) light is used to cross-link the polymer and bond it to the layer below.
When the structure is finished, it is bathed in a liquid containing living cells. The cells quickly attach to the inside and outside of the channels and begin growing just as they would in the human body, researchers said.
"They don't capture all the functional hallmarks of a real heart muscle, for example," she said.
A platform AngioChip could enable drug companies to detect dangerous side effects and interactions between organs. In future the lab-grown tissues could even be implanted into the body to repair organs damaged by disease.
The team has shown that the AngioChip can be implanted into a living animal, its artificial blood vessels connected to a real circulatory system. The polymer scaffolding itself biodegrades after several months.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories
Over 30 subscriber-only stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app